Lactoferrin Reduces Necrotizing Enterocolitis Severity by Upregulating Intestinal Epithelial Proliferation.

Area of Science:

• Neonatal Medicine
• Gastroenterology
• Immunology

Background:

• Necrotizing enterocolitis (NEC) is a severe intestinal disease in premature infants with high mortality.
• Current therapies for NEC are insufficient, necessitating novel treatment strategies.
• Lactoferrin, a protein in human milk, possesses immunomodulatory properties with potential protective effects against NEC.

Purpose of the Study:

• To investigate the mechanism by which lactoferrin impacts inflammation and proliferation in experimental NEC.
• To determine if lactoferrin downregulates inflammation and upregulates intestinal epithelial proliferation during NEC.

Main Methods:

• NEC was induced in mice via hypoxia, formula feeding, and lipopolysaccharide.
• Lactoferrin was administered daily to NEC and control mice.
• Intestinal tissue was analyzed for disease severity, inflammation markers (IL-6, TNF-α), stem cell expression (Lgr5), and proliferation markers (Ki67, β-catenin).

Main Results:

• Lactoferrin treatment significantly reduced NEC disease severity and inflammation markers.
• Lactoferrin increased intestinal stem cell expression (Lgr5) and proliferation (Ki67, β-catenin) in NEC mice.
• Lactoferrin administration did not negatively impact inflammation or proliferation in healthy control mice, indicating safety.

Conclusions:

• Lactoferrin administration effectively reduces intestinal injury in experimental NEC.
• Lactoferrin exerts its beneficial effects by downregulating inflammation and upregulating cell proliferation via the Wnt pathway.
• This study elucidates lactoferrin's mechanism of action in NEC and its potential role in enteral feeding strategies.